Bristol Myers Squibb (NYSE:BMY) Stock Rating Raised to “Strong-Buy” at Zacks Research

Bristol Myers Squibb (NYSE:BMY) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued to clients and investors on Wednesday, Zacks reports. Zacks Research also issued estimates for Bristol Myers Squibb’s Q3 2027 earnings at $1.56 EPS, FY2027 earnings at $6.24 EPS, Q1 2028 earnings at $1.48 EPS, Q2 2028 earnings at $1.38 EPS and FY2028 earnings at $5.23 EPS.

Several other research analysts have also recently issued reports on BMY. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 27th. Sanford C. Bernstein upgraded Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Cantor Fitzgerald restated a “neutral” rating and set a $59.00 price target (up from $54.00) on shares of Bristol Myers Squibb in a research note on Friday, July 31st. JPMorgan Chase & Co. lifted their price objective on Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $67.06.

Bristol Myers Squibb Trading Up 0.6%

NYSE BMY opened at $61.54 on Wednesday. The company’s 50-day moving average price is $64.44 and its 200-day moving average price is $60.15. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a market cap of $125.71 billion, a PE ratio of 13.56, a PEG ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb has a 12 month low of $42.52 and a 12 month high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts forecast that Bristol Myers Squibb will post 6.95 earnings per share for the current year.

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.05% of the company’s stock.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors have recently added to or reduced their stakes in the stock. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $27,000. Bayban purchased a new position in Bristol Myers Squibb in the fourth quarter worth $31,000. Addison Advisors LLC purchased a new position in Bristol Myers Squibb in the second quarter worth $32,000. Groupe la Francaise increased its position in shares of Bristol Myers Squibb by 562.9% during the second quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 501 shares in the last quarter. Finally, Arlington Trust Co LLC purchased a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $35,000. Institutional investors own 76.41% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks Research modestly raised its earnings forecasts for Bristol Myers Squibb, increasing estimates for third-quarter 2027 EPS to $1.56, full-year 2027 EPS to $6.24, first- and second-quarter 2028 EPS to $1.48 and $1.38, respectively, and full-year 2028 EPS to $5.23 from $5.17. The revisions suggest slightly improved expectations for the company’s future earnings. Zacks Research estimates
• Positive Sentiment: BMY was added to Zacks’ Rank #1 Strong Buy list and its Strong Buy income-stock list. The ratings may support demand for the shares, particularly because Bristol Myers Squibb offers significant cash flow and an attractive dividend profile. Zacks Strong Buy list
• Positive Sentiment: The company selected Onco360 as a restricted specialty-pharmacy provider for ZENBEXUS (iberdomide), its newly approved multiple-myeloma treatment. The distribution arrangement and clinical support could help the drug reach eligible patients during its commercial rollout. ZENBEXUS pharmacy network
• Positive Sentiment: Bristol Myers Squibb completed a Phase 1 lung-cancer combination study, providing incremental support for its immuno-oncology pipeline. Analysts also highlighted newer medicines as increasingly important in offsetting declines from mature products. Lung cancer study update
• Negative Sentiment: Despite the near-term positives, investors remain concerned about patent expirations and declines in established blockbuster products. Longer-term Zacks estimates remain below current-year expectations, underscoring the need for newer drugs such as ZENBEXUS to replace lost revenue.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.